BioCentury
ARTICLE | Finance

Coming out party

BridgeBio lifts the veil on its ATTR-focused Eidos subsidiary

April 29, 2017 12:21 AM UTC
Kumar said BridgeBio has decision-making autonomy in what it chooses to license and fund.

With the announcement of a $27 million commitment to its Eidos Therapeutics Inc. subsidiary, two-year-old BridgeBio Pharma is beginning to lift the veil on its portfolio of rare genetic disease plays.

Eidos, which is developing transthyretin (TTR)-mediated amyloidosis (ATTR) candidate AG10, is one of nine BridgeBio subsidiaries focused on single assets or diseases...

BCIQ Company Profiles

BridgeBio Pharma Inc.

BCIQ Target Profiles

Transthyretin (TTR)